BR0207867A - Sal de benzoilguanidina - Google Patents

Sal de benzoilguanidina

Info

Publication number
BR0207867A
BR0207867A BR0207867-8A BR0207867A BR0207867A BR 0207867 A BR0207867 A BR 0207867A BR 0207867 A BR0207867 A BR 0207867A BR 0207867 A BR0207867 A BR 0207867A
Authority
BR
Brazil
Prior art keywords
salt
benzoylguanidine
preparation
benzoylguanidine salt
benzoilguanidine
Prior art date
Application number
BR0207867-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Christian Eickmeier
Peter Sieger
Volkmar Koerner
Rolf Herter
Werner Rall
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BR0207867A publication Critical patent/BR0207867A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0207867-8A 2001-02-15 2002-02-14 Sal de benzoilguanidina BR0207867A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10106970A DE10106970A1 (de) 2001-02-15 2001-02-15 Neues Benzoylguanidinsalz
PCT/EP2002/001535 WO2002064563A1 (de) 2001-02-15 2002-02-14 Neues benzoylguanidinsalz

Publications (1)

Publication Number Publication Date
BR0207867A true BR0207867A (pt) 2004-03-23

Family

ID=7674094

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207867-8A BR0207867A (pt) 2001-02-15 2002-02-14 Sal de benzoilguanidina

Country Status (31)

Country Link
US (2) US20080025919A1 (cg-RX-API-DMAC7.html)
EP (1) EP1362030B1 (cg-RX-API-DMAC7.html)
JP (3) JP4408626B2 (cg-RX-API-DMAC7.html)
KR (1) KR100862176B1 (cg-RX-API-DMAC7.html)
CN (1) CN1222510C (cg-RX-API-DMAC7.html)
AT (1) ATE553078T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002250939B2 (cg-RX-API-DMAC7.html)
BG (1) BG66330B1 (cg-RX-API-DMAC7.html)
BR (1) BR0207867A (cg-RX-API-DMAC7.html)
CA (1) CA2434829C (cg-RX-API-DMAC7.html)
CY (1) CY1112878T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303277B6 (cg-RX-API-DMAC7.html)
DE (1) DE10106970A1 (cg-RX-API-DMAC7.html)
DK (1) DK1362030T3 (cg-RX-API-DMAC7.html)
EA (1) EA006245B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034708A (cg-RX-API-DMAC7.html)
EE (1) EE200300393A (cg-RX-API-DMAC7.html)
ES (1) ES2385472T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030653B1 (cg-RX-API-DMAC7.html)
HU (1) HU230035B1 (cg-RX-API-DMAC7.html)
IL (1) IL156934A (cg-RX-API-DMAC7.html)
NO (1) NO20033299D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ528081A (cg-RX-API-DMAC7.html)
PL (1) PL213300B1 (cg-RX-API-DMAC7.html)
PT (1) PT1362030E (cg-RX-API-DMAC7.html)
RS (1) RS52014B (cg-RX-API-DMAC7.html)
SI (1) SI1362030T1 (cg-RX-API-DMAC7.html)
SK (1) SK287830B6 (cg-RX-API-DMAC7.html)
UA (1) UA74625C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002064563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305365B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
US20110118262A1 (en) * 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
US10405746B2 (en) * 2014-04-14 2019-09-10 The University Of Memphis Research Foundation Wireless analog passive sensors
US12369831B1 (en) 2018-04-30 2025-07-29 Bashir I. Morshed Apparatus and method to capture body signals with conjugate coils and paired coils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
DE19843489B4 (de) * 1998-09-22 2006-12-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung
US6323207B1 (en) * 1998-09-22 2001-11-27 Boehringer Ingelheim Pharma Kg Benzoylguanidine derivatives
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof

Also Published As

Publication number Publication date
NO20033299L (no) 2003-07-22
HK1064093A1 (zh) 2005-01-21
RS52014B (sr) 2012-04-30
EP1362030A1 (de) 2003-11-19
JP2009235097A (ja) 2009-10-15
CN1491213A (zh) 2004-04-21
CA2434829C (en) 2009-12-08
IL156934A0 (en) 2004-02-08
BG108065A (bg) 2005-01-31
EE200300393A (et) 2003-12-15
JP2013107906A (ja) 2013-06-06
SK10202003A3 (sk) 2004-02-03
DK1362030T3 (da) 2012-07-09
UA74625C2 (en) 2006-01-16
CA2434829A1 (en) 2002-08-22
PL213300B1 (pl) 2013-02-28
EP1362030B1 (de) 2012-04-11
IL156934A (en) 2005-12-18
AU2002250939B2 (en) 2007-09-06
JP5745215B2 (ja) 2015-07-08
ZA200305365B (en) 2004-04-22
PT1362030E (pt) 2012-07-04
PL362129A1 (en) 2004-10-18
NO20033299D0 (no) 2003-07-22
CZ303277B6 (cs) 2012-07-11
EA006245B1 (ru) 2005-10-27
CZ20032210A3 (cs) 2003-12-17
SI1362030T1 (sl) 2012-07-31
BG66330B1 (bg) 2013-06-28
SK287830B6 (sk) 2011-11-04
HRP20030653A2 (en) 2005-06-30
HRP20030653B1 (en) 2012-06-30
JP2004518721A (ja) 2004-06-24
ATE553078T1 (de) 2012-04-15
HUP0303027A2 (hu) 2003-12-29
EA200300771A1 (ru) 2004-02-26
US20080025919A1 (en) 2008-01-31
ECSP034708A (es) 2003-12-24
KR20030075197A (ko) 2003-09-22
NZ528081A (en) 2005-10-28
JP4408626B2 (ja) 2010-02-03
CN1222510C (zh) 2005-10-12
US20080241077A1 (en) 2008-10-02
HU230035B1 (hu) 2015-05-28
YU61503A (sh) 2006-05-25
HUP0303027A3 (en) 2010-04-28
WO2002064563A1 (de) 2002-08-22
KR100862176B1 (ko) 2008-10-09
DE10106970A1 (de) 2002-08-29
CY1112878T1 (el) 2016-04-13
ES2385472T3 (es) 2012-07-25

Similar Documents

Publication Publication Date Title
BR0111034A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
DK0733046T3 (da) Benzoylguanidiner, deres fremstilling og anvendelse i medikamenter
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
BR0113710A (pt) Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade
CA2424664A1 (en) Novel non-imidazole compounds
SV2002000776A (es) Nuevas imidazotriazinonas sustituidas ref.lea 34 985-sv
MA26937A1 (fr) Nouvelle composition pharmaceutique.
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
NO20024175L (no) Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
MEP33708A (hr) Farmaceutske smješe koje obuhvataju inhibitor hmg coa reduktaze
BR0008379A (pt) Epotilonas modificadas em c-21
ATE337014T1 (de) Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen
BR0207509A (pt) Pirazolilpirimidinas
BR0115518A (pt) Kit de repinotan
BR9916887A (pt) Uso de derivados de pirimidina
EE200300547A (et) Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
BR0012169A (pt) Dihidrobenzodiazepinas e seu uso no tratamento de dislipidemia
BR0317623A (pt) Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
BR0103048A (pt) Derivados de n-triazolilmetil-piperazina como antagonistas de receptores de neuroquinina
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
BR9911679A (pt) Sais de paroxetina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]